GH Guardant Health, Inc. stock chart & analysis

Conviction 40HealthcareScan · Fri, Nov 6, 2026

Guardant Health, Inc. (GH) closed at $150.87 (-1.67%) on Nov 6, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 37, RS Rating 93, -20.8% from its 52-week high, +48.1% year to date. Sector: Healthcare · Services-Medical Laboratories.

GH$150.87-1.67%

ResistanceSupportVol 14Insider sellCongress buyCongress sell

Loading chart…

Guardant Health, Inc.Services-Medical Laboratorieswww.guardanthealth.com ↗

Price150.87

Change-1.67%

Gap-6.60%

Rel volume3.58×

Avg volume2.12M

Avg $ vol349.52M

SMA 20167.43

SMA 50169.33

SMA 200131.73

Price vs 50-10.65%

Price vs 200+14.85%

MA stackmixed

50/200 cross—

Supertrenddown · 176.55

RSI (14)37

MACD hist-2.00

MACD crossbear · 1d

Stoch %K / %D30 / 26

ADX (14)18

+DI / −DI14 / 34

RSI divergence—

MACD divergence—

ATR %6.68%

ADR %5.82%

52w high191.05

52w low74.55

From 52w high-20.81%

Above 52w low+102.95%

New 52w highNo

SqueezeOff

Bollinger width21.63%

%B0.05

Donchian pos30.09%

Donchian high186.03

Donchian low136.35

AVWAP (52w high)165.63

vs AVWAP high-8.65%

AVWAP (52w low)143.29

vs AVWAP low+5.59%

OBV trendDown

Chaikin MF (20)0.09

Today vs 20d3.58×

Avg vol (14d)2.36M

Avg vol (20d)2.12M

Avg $ vol (20d)349.52M

Market cap20.47B

RS Rating93 / 99

RS 3m (vs SPY)-4.65%

RS 6m (vs SPY)+58.40%

RS line new highNo

Trend template6/8

Technical rank67.6

1 week-15.38%

1 month-8.61%

3 months-9.51%

6 months+58.10%

1 year+59.18%

YTD+48.13%

P/E-49.17

P/B-74.19

P/S20.84

P/FCF-87.82

EPS-3.32

Div yield—

ROE150.88%

ROA-22.08%

Debt/Eq-5.45

Current3.60

EV/EBITDA-52.69

Gross margin64.46%

Net margin-42.39%

Rev growth32.88%

EPS growth4.61%

Price target203.94

Target upside34.79%

Analyst ratingBuy

Institutional112.20%

Ent. value20.94B

Revenue360.98M

Net income-124.36M

Gross profit236.15M

Free cash flow-233.07M

IndustryServices-Medical Laboratories

ExchangeNasdaq

Shares out132.6M

Employees2.51K

ListedThu, Oct 4, 2018

Free float126.19M

Float %96.2%

Short interest—

Days to cover—

Short volume32.6%

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est−$0.93 vs −$0.68

Last surprise-36.8% miss

Setup gradeD

Conviction40 / 100

Pattern quality—

Tech rank67.6 / 100

Group rank23 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance188.54

Support156.68

Days since event—

Candle confirm—

Financials as of Wed, Sep 30, 2026 · quarterly.

GH technical analysis

Trend

GH's moving averages are mixed — no clean uptrend or downtrend. It closed 10.7% below the 50-day ($169.33) and 14.8% above the 200-day ($131.73). ADX(14) at 18 points to a weak trend — more range than direction. It meets 6 of 8 trend-template criteria.

Momentum

RSI(14) is 37, in the bearish half of its range. MACD crossed below its signal line one session ago. Its RS Rating of 93 puts its weighted 12-month performance ahead of about 93% of the US market.

Volume and volatility

Volume on the latest session ran 3.6× its 20-day average. It trades about $349.5M a day on average. ATR(14) is $10.10, 6.7% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (0.09) shows accumulation.

Key levels

The chart pattern's support is $156.68 and its resistance $188.54. The 52-week range is $74.55 to $191.05; price is 20.8% below the high and 103.0% above the low. The VWAP anchored at the 52-week high is $165.63, above price.

Performance

GH returned -15.4% (1 week), -8.6% (1 month), -9.5% (3 months), +58.1% (6 months), +59.2% (1 year), +48.1% (year to date).

About Guardant Health, Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Services-Medical Laboratories · Listed 2018 · 2,506 employees

Congress activity

Disclosed STOCK Act trades in GH · 2 recent

All disclosures →

Member	Side	Amount	Traded	Filed	PTR
Jonathan Jackson house · D · IL · traded 2026-09-28	Buy	$15K–$50K	2026-09-28	2026-10-19	PDF
Sheldon Whitehouse senate · D · RI · traded 2025-11-21	Buy	$1K–$15K	2025-11-21	2025-12-01	PDF

Insider activity

SEC Form 4 transactions in GH · open-market 2 sells

Insider	Side	Shares	Value	Traded	Filed
Hidalgo Medina Manuel Director · Common Stock · 2026-10-17	Exercise	232	—	2026-10-17	2026-10-19
Hidalgo Medina Manuel Director · Restricted Stock Units · 2026-10-17	Exercise	232	—	2026-10-17	2026-10-19
Tariq Musa Director · Common Stock · 2026-10-16	Sell	116	$19K	2026-10-16	2026-10-19
Tariq Musa Director · Common Stock · 2026-10-15	Exercise	250	—	2026-10-15	2026-10-19
Tariq Musa Director · Restricted Stock Units · 2026-10-15	Exercise	250	—	2026-10-15	2026-10-19
Azar Alex M II Director · Common Stock · 2026-10-14	Sell	69	$11K	2026-10-14	2026-10-15
Bell Michael Brian Chief Financial Officer · Common Stock · 2026-10-01	Exercise	3.32K	—	2026-10-01	2026-10-02
Bell Michael Brian Chief Financial Officer · Common Stock · 2026-10-01	Tax	3.91K	$684K	2026-10-01	2026-10-02
Bell Michael Brian Chief Financial Officer · Restricted Stock Units · 2026-10-01	Exercise	1.87K	—	2026-10-01	2026-10-02
Bell Michael Brian Chief Financial Officer · Restricted Stock Units · 2026-10-01	Exercise	2.08K	—	2026-10-01	2026-10-02

SEC filings

EDGAR filings in GH · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.